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Mitochondrial Replacement Therapy: 
How a Government for the People, Failed 
the People 
 
JEFFERY MARK SAUER* 
 
Despite having the potential to significantly reduce the 
passage of many lethal diseases and devastating birth de-
fects, mitochondrial replacement therapy—a controversial 
medical procedure in which mitochondrial RNA from a 
healthy female replaces the mitochondrial RNA from the in-
tended mother in vitro—will have no place in the United 
States anytime soon. Under the guise of purported safety 
concerns and ethical dilemmas, the Republican Congress 
used its “power of the purse” to halt any and all research 
furthering mitochondrial replacement therapy, notwith-
standing the fact that many leaders in the medical commu-
nity have advocated for further research. Several developed 
countries have already implemented limited applications of 
the procedure. However, as long as Congress continues to 
abuse its constitutional appropriations power in a manner 
inconsistent with the original intent of the framers, policies 
that can greatly benefit society as a whole will be sacrificed 
in the name of partisanship and narrow-mindedness. 
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INTRODUCTION 
“We are on the cusp of being able to do [gene editing] safely, 
and the prospect of telling a parent that they won’t have ac-
cess to these therapies is morally untenable . . . A ban doesn’t 
make sense . . . .”1 
Leo Chapman-Nesseth was born June 6, 2009 in Minnesota.2 
Described by his parents Andrew and Lindsay as “perfectly normal 
and healthy through the first six months of his life,” Leo exhibited 
many of the conventional characteristics of a newborn: a pinkish 
color, ten fingers, ten toes, and a rambunctious personality.3 At just 
eleven months old, Leo was diagnosed with Alpers’ disease,4 an au-
tosomal recessive disease caused by a mutation in mitochondrial 
DNA with no cure and no method to slow its progression.5 Leo 
quickly began to experience symptoms such as seizures and liver 
failure.6 He died just three days after celebrating his first birthday.7 
“Each year, 1,000 to 4,000 children in the United States are born 
with a mitochondrial disease.”8 Hope may be on the horizon, how-
ever, as doctors and researchers now believe that it may be possible 
to prevent the passage of mutated mitochondrial DNA from mothers 
to their offspring via a controversial technique still in the early 
																																																																																																																												
 1  Alex Pearlman, Scientists Argue the US Ban on Human Gene Editing Will 
Leave It Behind, MOTHERBOARD (Aug. 4, 2016, 2:00 PM), https://motherboard. 
vice.com/en_us/article/nz7dp8/scientists-argue-the-us-ban-on-human-gene-edit-
ing-will-leave-it-behind (quoting bioethicist James Hughes, Executive Director of 
the Institute for Ethics and Emerging Technologies). 
 2  Daily Globe News, Family Raises Awareness for Rare Disease, GLOBE 
(July 1, 2010, 9:49 PM), http://www.dglobe.com/news/1372692-family-raises-
awareness-rare-disease. 
 3  Id.  
 4  Id.; Alpers’ Disease Information Page, NAT’L INST. NEUROLOGICAL DIS-
ORDERS & STROKE, https://www.ninds.nih.gov/Disorders/All-Disorders/Al pers-
Disease-Information-Page (last modified June 15, 2018). 
 5  Alpers’ Disease Information Page, supra note 4. 
 6  Nidhi Subbaraman, ‘3-Parent Babies’ Could Eliminate Rare Diseases, but 
US Lawmakers Have Blocked the Technology, BUZZFEED NEWS (Sept. 13, 2016, 
9:02 AM), https://www.buzzfeed.com/nidhisubbaraman/mitochondrial-disease-
congress?utm_term=.hcAjPeqYqW#.vpYrQ9YRYj. 
 7  Id. 
 8  Frequently Asked Questions, UNITED MITOCHONDRIAL DISEASE FOUND., 
http://www.umdf.org/faq-page-1/ (last visited Sept. 14, 2018). 
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stages of experimentation. This process is known as mitochondrial 
replacement therapy.9 Despite the safety concerns10 associated with 
any groundbreaking medical procedure, as well as the ethical di-
lemma that germline-modified offspring from three parents pre-
sents,11 an expert panel of scientists and bioethicists from the Na-
tional Academies of Sciences and Institute of Medicine concluded 
that it was ethically permissible to “go forward, but with caution” 
with limited experimentation of mitochondrial replacement tech-
niques at this point.12  
Unfortunately, any momentum that had progressed in transition-
ing towards human trials in mitochondrial replacement therapy was 
abruptly halted by Section 749 of the Consolidated Appropriation 
Act of 2016, which precludes the Food and Drug Administration 
(“FDA”) from evaluating any “research in which a human embryo 
is intentionally created or modified to include a heritable genetic 
modification.”13 In short, the largely Republican14 Congress pre-
cluded the FDA from pursuing what could be a potentially life-sav-
ing technology for future generations.15 It will now be seemingly 
																																																																																																																												
 9  Eli Y. Adashi & Glenn Cohen, Mitochondrial Replacement Therapy: Un-
made in the USA, 317 JAMA 574, 574–75 (2017), https://jamanetwork.com/ jour-
nals/jama/fullarticle/2601488.  
 10  Id. at 574 (noting that safety concerns surrounding mitochondrial replace-
ment therapy include possible mismatches between donors and recipients of Mi-
tochondrial DNA, as well as the possibility that some of the mutated Mitochon-
drial DNA at issue may be transferred which would result in disease as well).  
 11  Id. at 575.  
 12  Joel Achenbach, Ethicists Approve ‘3 Parent’ Embryos to Stop Diseases, 
but Congressional Ban Remains, WASH. POST (Feb. 3, 2016), https://www.wash-
ingtonpost.com/news/speaking-of-science/wp/2016/02/03/to-prevent-disease-
ethicists-approve-creation-of-embryos-with-three-genetic-parents/?utm_term 
=.ccc4a92b133e (quoting chairman Jeffrey Kahn, bioethicist at John Hopkins 
University); see INST. OF MED., THE NAT’L ACADEMIES OF SCI., ENG’G & MED., 
REPORT IN BRIEF OF MITOCHONDRIAL REPLACEMENT TECHNIQUES: ETHICAL, SO-
CIAL, AND POLICY CONSIDERATIONS (2016), http://www.nationalacademies.org 
/hmd/~/media/Files/Report%20Files/2016/Mitochondrial%20Replace-
ment%20Techniques/MitoEthics-RIB.pdf. 
 13  Consolidated Appropriations Act, 2016, Pub. L. 114-113, § 749, 129 Stat. 
2242, 2283 (2015).  
 14  2016 House Election Live Results, 270TOWIN, https://www.270towin.com 
/2016-house-election-results-live/ (last visited Sept. 15, 2018) (showing House 
election results and Senate election results in 2016). 
 15  Adashi & Cohen, supra note 9, at 574–75. 
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impossible for the FDA to eventually make a definitive ruling on the 
safety and efficacy of the procedure.16 To muddy the waters even 
further, the congressional record is completely silent on the identity 
of the supporters of the ban, and the exact motives for including the 
ban in the budget bill remain uncertain.17  
This Note will first outline exactly what mitochondrial replace-
ment therapy is and what experimentation of this technique entails. 
Part II will discuss the history and purpose of the Constitution’s Ap-
propriations Clause, demonstrating its clear potential for abuse and 
potential violation of the separation of powers doctrine. Part III will 
then illustrate historical Republican opposition and hostility towards 
disruptions with the natural birth cycle in support of my hypothesis, 
beginning with abortion and continuing with in vitro fertilization 
(“IVF”) and stem-cell research. Part IV will then provide a recom-
mended resolution between the FDA and Congress upon renewal of 
the budget bill in 2018.  
I. MITOCHONDRIAL DISEASE: THE DIAGNOSIS, THE TREATMENT, 
AND THE IMPLICATIONS 
A. What Is Mitochondrial Disease and Whom Does It Affect? 
Mitochondria are organelles that are responsible for producing 
energy within cells in order for the cells to function properly.18 Mi-
tochondria also contain a small amount of genetic material—their 
own DNA—distinct from the DNA that is ordinarily found in a 
cell’s nucleus.19 Mitochondrial DNA is thus passed down from a 
mother to her child, and any mutations that occur in the mitochon-
drial genome can in turn lead to a plethora of mitochondrial diseases 
																																																																																																																												
 16  Achenbach, supra note 12.  
 17  Adashi & Cohen, supra note 9, at 574–75. 
 18  Mike Orcutt, The Unintended Consequence of Congress’s Ban on Designer 
Babies, MIT TECH. REV. (Aug. 26, 2016), https://www.technologyreview.com 
/s/602219/the-unintended-consequence-of-congresss-ban-on-designer-babies/#c 
omments. 
 19  Id.; see also Advisory on Legal Restrictions on the Use of Mitochondrial 
Replacement Techniques to Introduce Donor Mitochondria into Reproductive 
Cells Intended for Transfer into a Human Recipient, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/ucm 
570185.htm (last updated Mar. 16, 2018) [hereinafter Advisory]. 
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ranging in severity from relatively mild to potentially life-threaten-
ing.20 Because mitochondria are the primary sources of energy pro-
duction for all cells in the body, mitochondrial diseases typically 
manifest in tissues that rely heavily on energy production, including 
brain, heart, muscle, pancreas, and kidney cells.21 As many as 4,000 
children are born with mitochondrial diseases in the United States 
every year, and there are no licensed cures or treatments for these 
debilitating diseases.22 
B. How Can Mitochondrial Replacement Therapy Prevent Mito-
chondrial Disease? 
Although mitochondrial disorders are believed to be incurable 
per se, researchers now believe that it may be possible to prevent 
them from occurring at all through mitochondrial replacement ther-
apy.23 Mitochondrial replacement therapy is the “combining [of] the 
nucleus from the egg of an affected woman with the cytoplasm from 
an unaffected woman that contains healthy mitochondria.”24  
Dr. Shoukhrat Mitalipov, Director of Oregon Health and Science 
University’s Center for Embryonic Cell and Gene Therapy, has 
demonstrated “in monkeys that a replacement mitochondrial ge-
nome from another mother can be effectively and safely passed to 
offspring along with the nuclear DNA from the actual mother.”25 
Mitalipov had been working closely with the FDA in order to de-
velop future plans for human testing of mitochondrial replacement 
therapy prior to the passage of the Consolidated Appropriation Act 
																																																																																																																												
 20  See Gretchen Vogel, For Boys Only? Panel Endorses Mitochondrial Ther-
apy, but Says Start with Male Embryos, SCI. (Feb. 3, 2016, 2:00 PM), 
http://www.sciencemag.org/news/2016/02/boys-only-panel-endorses-mitochond 
rial-therapy-says-start-male-embryos [hereinafter Vogel, For Boys Only?] 
(“Males can’t pass along the mitochondrial DNA that is altered in the proce-
dure . . . . Mitochondria] carry their own DNA, coding for 37 genes, which is 
passed down from mother to child through the mitochondria in the egg cyto-
plasm.”) (emphasis added). 
 21  DANIELA BARBERY ET AL., SHOULD THE U.S. APPROVE MITOCHONDRIAL 
REPLACEMENT THERAPY? 8 (2015).  
 22  Orcutt, supra note 18. 
 23  Adashi & Cohen, supra note 9, at 574. 
 24  Id. 
 25  Orcutt, supra note 18.  
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of 2016.26 Mitalipov and his colleagues have also demonstrated that 
this “three parent” approach through the use of IVF of human em-
bryos is medically feasible.27  
C. The Social and Ethical Concerns of Mitochondrial Replace-
ment Therapy: How Do We Get There? 
Although mitochondrial replacement therapy could one day 
emerge as the exclusive method to allow women with mitochondrial 
diseases to have healthy children, the experimental method is cer-
tainly not without social and ethical challenges.28 Though it would 
be a stretch to say doctors and scientists are, in fact, “play[ing] 
God,”29 it is feasible to sympathize with those who are uncomforta-
ble with the idea of scientists modifying human germlines. Some 
fear mitochondrial replacement therapy may be the first step in one 
day allowing a market for “designer babies” to flourish.30  
																																																																																																																												
 26  Id.; see Consolidated Appropriations Act, 2016, Pub. L. 114-113, 129 Stat. 
2242 (2015). 
 27  Orcutt, supra note 18.  
 28  See generally Ian Sample, ‘Three-Parent’ Babies Explained: What Are the 
Concerns and Are They Justified?, GUARDIAN (Feb. 2, 2015, 10:56 AM), https:// 
www.theguardian.com/science/2015/feb/02/three-parent-babies-explained (dis-
cussing various ethical and religious objections scientists and others have raised 
regarding the procedure). 
 29  John D. Loike & Nancy Reame, Opinion: Ethical Considerations of 
“Three-Parent” Babies, SCIENTIST (Dec. 22, 2016), https://www.the-scien-
tist.com/?articles.view/articleNo/47725/title/Opinion--Ethical-Consideratio ns-
of--Three-Parent--Babies/ (discussing the dilemma scientists researching mito-
chondrial replacement therapy face due to the popular belief that genetic modifi-
cations are akin to “play[ing] God”). Loike and Reame note, however, that “hu-
mans have engaged in genetic modifications of plants and animals for thousands 
of years” without any ethical roadblocks, and are further engaged in a form of 
genetic screening known as preimplantation genetic diagnosis (“PGD”), which 
allows couples engaging in IVF to “screen” embryos for selection by eliminating 
those that possess various genetic diseases. Id. 
 30  See Pam Belluck, Gene Editing for ‘Designer Babies’? Highly Unlikely, 
Scientists Say, N.Y. TIMES (Aug. 4, 2017), https://www.nytimes.com/2017 
/08/04/science/gene-editing-embryos-designer-babies.html. Belluck notes that 
with modern-day science being one-step closer to repairing single gene mutations 
and defects in order to bypass serious or even fatal diseases, it may mean that we 
are also closer to “customizing” babies with “Lin-Manuel Miranda’s imagination 
or Usain Bolt’s speed.” Id. This is misplaced for a variety of scientific reasons, 
however, discussed in detail in the article. See id. 
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Scientists in support of mitochondrial replacement therapy rebut 
these assertions, however, by pointing out that mitochondrial re-
placement therapy is more akin to various forms of preventative 
care, such as preimplantation genetic diagnosis of embryos to screen 
for genetic diseases, as opposed to individual gene shopping.31 Fur-
thermore, Philip Yeske, Science and Alliance Officer for the United 
Mitochondrial Disease Foundation, points out that only a very nar-
row population—“women of childbearing age who have mitochon-
drial disorders and who want to have children”—stand to benefit 
from the experimental technique in the first place; therefore, it is not 
akin to making designer babies or selecting genetic traits.32  
The unintended social and legal consequences that may stem 
from “three-parent babies” are a second ethical roadblock for scien-
tists and policymakers.33 The term “three-parent babies” has grown 
to be frequently associated with mitochondrial replacement therapy 
due to the nature of the procedure, which involves contributions 
from three individuals: (1) the nucleus from the egg of an affected 
mother, (2) the cytoplasm from an unaffected woman that contains 
healthy mitochondria, and (3) the sperm of the father.34 Because the 
nature of the procedure is seen as so fundamentally unconventional 
compared to how the average couple would go about having a child, 
it has led many to question how mitochondrial donation should be 
regulated in regards to legal issues such as parental rights, as well as 
																																																																																																																												
 31  See Sample, supra note 28 (emphasizing that a change in law to allow mi-
tochondrial replacement therapy research to continue would not allow “designer 
babies” to come about because the typical defining human characteristic traits 
such as eye and hair color are controlled by DNA in the cell nucleus, not the cell’s 
mitochondria). 
 32  Orcutt, supra note 18. Yeske notes that scientists researching mitochon-
drial replacement therapy “don’t feel it’s a slippery slope at all,” due to the narrow 
target recipients of the procedure in the first place. Id. 
 33  See Sample, supra note 28 (note that the graphic entitled “[t]hree-person 
embryos” outlines the two prominent mitochondrial replacement therapy tech-
niques—maternal spindle transfer and pronuclear transfer—in which DNA from 
three different individuals is utilized in the creation of the embryo). 
 34  See Adashi & Cohen, supra note 9, at 574; César Palacios-González, Mi-
tochondrial Replacement Techniques: Egg Donation, Genealogy and Eugenics, 
34 MONASH BIOETHICS REV. 37, 38 (2016).  
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whether the resulting offspring have a legal right to know their true 
lines of ancestry.35  
This concern, although valid and well placed, is largely over-
blown for several reasons. First, from a practical standpoint, the mi-
tochondrial DNA donation would come from an anonymous donor 
who has no legal rights over the child and is not involved in the 
child’s upbringing in any way.36 Therefore, as is the case with other 
reproductive technologies involving third parties such as oocyte do-
nation and gestational surrogacy, mitochondrial replacement ther-
apy is likely capable of establishing similar legal methods that in 
fact protect donor privacy.37 From a strictly scientific standpoint, 
this argument lacks muster as well because all 20,000 genes located 
on the child’s twenty-three pairs of chromosomes would still come 
from the child’s intended mother and father.38 The DNA contributed 
by the donor woman, which sits in the mitochondria, would consti-
tute less than 0.2% of the child’s DNA profile.39 
II. THE BAN ON MITOCHONDRIAL REPLACEMENT THERAPY: HOW 
CONGRESS HAS HELD THE FDA HOSTAGE THROUGH THE  
APPROPRIATIONS CLAUSE 
Although the benefits that mitochondrial replacement therapy 
would have for women susceptible to passing along mitochondrial 
diseases to their offspring are obvious, a congressional ban stands in 
the way of anyone actually receiving these benefits. Congress disa-
bled the FDA’s authority on the matter and swiftly put an end to all 
																																																																																																																												
 35  See Loike & Reame, supra note 29. Loike proposes that because genetic 
contributions from mitochondrial DNA of a donor is essential for the development 
of the child, that genetic contribution from mitochondrial DNA should not be con-
sidered irrelevant to the status of parenthood, but should follow an already estab-
lished avenue of determining or relinquishing parental rights, such as the system 
in place for adoption. Id. 
 36  Sample, supra note 28.  
 37  Loike & Reame, supra note 29 (“Given its potential for permanent altera-
tions of DNA, this technology should not be viewed as equivalent to classical 
organ donation, but rather treated with precautions in line with other germline 
interventions, such as egg or sperm donation, for which regulatory practices are 
already in place. Using these as a framework, governments and the scientific com-
munity should invest time and money into making [mitochondrial replacement 
therapy] widely available to patients.”). 
 38  See Sample, supra note 28. 
 39  Id. 
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mitochondrial replacement therapy research in the United States 
with nothing more than a ten-line provision in Section 749 of the 
Consolidated Appropriations Act of 2016.40  
Despite the United Kingdom’s approval in February 2015 of the 
technology,41 the United States Congress was able to successfully 
shut down this research notwithstanding much opposition and hos-
tility from scientists, doctors, and patients throughout the country.42 
As Dr. Shoukhrat Mitalipov has pointed out, despite the fact that the 
United States was “one of the pioneers” in developing mitochondrial 
replacement therapy, 43  clinical implementation of the procedure 
will only take place in other countries such as the United Kingdom.44 
																																																																																																																												
 40  Consolidated Appropriations Act, 2016, Pub. L. 114-113, § 749, 129 Stat. 
2242, 2283 (2015). 
 41  See Ewen Callaway, Scientists Cheer Vote to Allow Three-Person Em-
bryos, NATURE (Feb. 3, 2015), http://www.nature.com/news/scientists-cheer-
vote-to-allow-three-person-embryos-1.16843 (noting that the United Kingdom’s 
House of Commons vote to legalize mitochondrial replacement therapy by a vote 
of 382 to 128 allows the United Kingdom to become the first country in the world 
to allow clinical applications of mitochondrial replacement therapy). 
 42  See Subbaraman, supra note 6. Eli Adashi, Professor of Medical Science 
at Brown University, described the ban as “something unusual, perhaps disturb-
ing, about Congress laying down the law when the scientific community and pub-
lic are just beginning to understand the issue.” Id. (emphasis added). Lindsay 
Chapman, an advocate of mitochondrial replacement therapy after losing her son 
Leo to Alpers’ Disease in 2010, has said that she “can’t even fathom why they 
would think that that would be something we shouldn’t be researching and 
frankly, doing clinical trials on . . . There’s just something inside of me that 
screams at the idea that somebody else would stand in the way.” Id.; see supra 
note 2 and accompanying text. Philip Yeske stated “[t]hey were very clear in their 
report – they saw no ethical reason to limit human clinical studies for mitochon-
drial replacement therapy.” Subbaraman, supra note 6. 
 43  Id.  
 44  See Rosa J. Castro, Mitochondrial Replacement Therapy: The UK and US 
Regulatory Landscapes, J.L. & BIOSCIENCES 726, 735 (2016), https://www.ncbi 
.nlm.nih.gov/pmc/articles/PMC5570689/pdf/lsw051.pdf (“The different stances 
of the UK and the USA with regard to MRT can probably be explained as the 
result of a combination of (i) historical events, including the adverse reports from 
cytoplasmic transfer treatments in the USA, (ii) the lack of a broader dialogue 
with experts and the public, (iii) the lack of a specialized authority in charge of 
reproductive technologies, and (iv) the deeply polarized abortion and ‘person-
hood’ debates.”). 
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Congress was able to implement the ban effectively because the fed-
eral legislature potentially possesses the most powerful tool of any 
of the three branches of government: the power of the purse.45  
A. The Appropriations Clause: “The Power of the Purse” 
The federal legislature’s appropriations power stems specifi-
cally from Article I, Section 9 of the Constitution. The Appropria-
tions Clause states the following: “No Money shall be drawn from 
the Treasury, but in Consequence of Appropriations made by Law; 
and a regular Statement and Account of the Receipts and Expendi-
tures of all public Money shall be published from time to time.”46 In 
essence, for the executive branch and any federal agencies to act in 
order to achieve their goals and policies, Congress must affirma-
tively authorize the funds required for these projects.47  
In the case of mitochondrial replacement therapy, the FDA is the 
federal agency seeking congressional appropriation of federal fund-
ing. The clinical use of mitochondrial replacement therapy in the 
United States falls within the FDA’s regulatory authority because 
the FDA’s oversight includes ensuring safe transfers of human cells 
and tissues into human recipients.48 This includes the transfer of re-
productive cells and tissues used in mitochondrial replacement ther-
apy when mitochondria from a donor woman are transferred into the 
cells of a woman at risk for passing along mitochondrial disease 
traits.49 Therefore, since Congress included provisions in Section 
749 of the Consolidated Appropriations Act of 2016 that prohibit 
																																																																																																																												
 45  “[T]he Constitution’s most significant check on Executive power: the Pres-
ident can spend funds on a program only if he can convince Congress to appropri-
ate the money.” Kate Stith, Congress’ Power of the Purse, 97 YALE L.J. 1343, 
1350 (1988) (emphasis added) (citation omitted). “Among the duties—and among 
the rights, too—of this House, there is perhaps none so important as the control 
which it constitutionally possesses over the public purse.” Id. (emphasis added) 
(citation omitted).  
 46  U.S. CONST. art. I, § 9, cl. 7. 
 47  See Stith, supra note 45, at 1350. 
 48  Advisory, supra note 19. “The Food and Drug Administration’s (FDA) 
Center for Biologics Evaluation and Research regulates an array of diverse and 
complex biological products . . . including human cell and gene therapy products 
and human cells and tissues. FDA’s oversight includes ensuring that human cells 
and tissues intended for transfer into a human recipient, including reproductive 
cells and tissues, are free from infectious diseases.” Id. 
 49  Id. 
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the FDA from even accepting applications for clinical research in-
volving gene editing in humans, clinical research of mitochondrial 
replacement therapy in humans cannot legally proceed in the United 
States at this time.50 This holds true even if the source of funding for 
these experiments is from private third parties. The Consolidated 
Appropriations Act of 2016 prohibits the use of any federal funds to 
handle applications for the experiments.51 The FDA is “disabled” 
from approving anyone to conduct experiments, even if they were 
able to secure funding on their own.52  
The appropriations requirement imposed on the executive 
branch by the legislature is necessary because if Congress could not 
prohibit federal agencies from withdrawing funds from the Treas-
ury, the executive branch could essentially compel its own legisla-
tion by spending money at will in order to push its own policies.53 
The Framers’ intent, according to James Madison,  was to assure 
that “the [legislature] alone ha[d] access to the pockets of the peo-
ple.”54 What frustrates this issue even further, however, is that it has 
never been seriously proposed or alleged that Congress would, or 
even could, “violate” the Appropriations Clause by failing to effec-
tively exercise control over federal expenditures.55 Notwithstanding 
																																																																																																																												
 50  Id.  
 51  See Consolidated Appropriations Act, 2016, Pub. L. 114-113, § 749, 129 
Stat. 2242, 2283 (2015). 
 52  See Achenbach, supra note 12 (“The omnibus fiscal 2016 budget bill 
passed by Congress late last year contained language prohibiting the government 
from using any funds to handle applications for experiments that genetically alter 
human embryos.”). Dr. Shoukhrat Mitalipov described the function of the ban as 
follows: “It seems like the FDA is disabled in this case by Congress . . . . At this 
point we’re still not clear how to proceed.” Id. (emphasis added). 
 53  See Stith, supra note 45, at 1349. 
 54  Abner J. Mikva, Congress: The Purse, the Purpose, and the Power, 21 GA. 
L. REV. 1, 3 (1986) (citing THE FEDERALIST No. 48, at 334 (James Madison) (J. 
Cooke ed., 1961)). 
 55  Stith, supra note 45, at 1344–45. Stith discusses the general assumption by 
constitutional scholars that “Congress has exclusive authority to construe and im-
plement the appropriations clause,” yet no one has really ever “considered the 
possibility that Congress itself may violate the clause.” Id. at 1345 n.5. But see 
Dick Cheney et al., The Constitution and the Budget Process, in CONSTITUTIONAL 
CONTROVERSIES 63, 95 (Robert A. Goldwin et al. eds., 1987) (suggesting that as-
pects of legislative budget practice are “not in keeping with . . . the spirit of the 
appropriations clause”).  
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the diverse interpretations of the intended effect of the Appropria-
tions Clause, it remains concrete that, as used today, the appropria-
tions power allows Congress to dictate exactly how federal agencies 
allocate the amount of federal funding appropriated to them,56 even 
in ways that are directly adverse to the executive branch or society 
as a whole. 
B. The Purpose of the Appropriations Power, as Intended by the 
Framers of the Constitution 
Based on the Framers’ placement of the Appropriations Clause 
in Section 9 Article I, rather than in Section 8 with most other con-
gressional powers and responsibilities, the appropriations require-
ment was arguably not meant to be a grant of affirmative power to 
shape policy or push a partisan agenda.57 In practice, however, the 
appropriations power does more than allocate funding to specified 
agencies and projects. This power delineates the scope of congres-
sionally authorized activities and forbids the progression of those 
activities Congress opposes.58 Although this safeguard serves as a 
valuable tool to protect abuses of power and discretion by the exec-
utive branch and federal agencies, it simultaneously allows the leg-
islature to abuse its own power by essentially vetoing policies that 
can greatly benefit society at large, such as mitochondrial replace-
ment therapy. 
The ideological premise behind Congress possessing sole au-
thority to affirmatively dictate how all federal funds are allocated is 
seemingly at odds with the separation of powers doctrine. Baron de 
Montesquieu first popularized the doctrine of separation of powers 
as the best strategy to avoid tyranny—the equal constitutional dis-
																																																																																																																												
 56  See Stith, supra note 45, at 1353 (“These strings, or conditions of expendi-
ture, constitute legislative prescriptions that bind the operating arm of govern-
ment. Occasionally, conditions may be stated in an appropriations statute itself. 
For instance, an appropriations act may provide that ‘[n]o part of any appropria-
tion contained in this Act shall be used . . . for publicity or propaganda pur-
poses . . .’ Alternatively, the appropriations act may require that the recipient fed-
eral agency allocate the amount appropriated among certain activities or in ac-
cordance with certain conditions.” (emphasis added)). 
 57  See id. at 1349. 
 58  See id. at 1356. 
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tribution of power among three branches of government: a legisla-
tive branch, executive branch, and judicial branch.59 Proponents of 
the Constitution relied on Montesquieu’s theory in dividing the 
power of government equally among the three branches in a way 
best described by Abner J. Mikva: “Congress would manage the 
purse, the President would wield the sword, and the courts would 
exercise the power of review [to] protect individual liberties in the 
newly formed federal government.”60 In other words, the individu-
als comprising each branch should have the “necessary constitu-
tional means and personal motives to resist encroachment of the oth-
ers.”61 In reality, however, how is the executive branch expected to 
“wield its sword” effectively, if at all, if Congress is granted plenary 
authority to dictate when and how it does so? 
The answer lies in an interpretation of the Constitution that the 
appropriations power was never meant to be used as a weapon that 
allows Congress to affirmatively push its own policies. 62  If the 
Framers truly intended the power of the purse to be the strongest and 
most effective of all governmental powers, then it would also mean 
that the Framers intended to give the legislative branch a significant 
advantage over the executive branch in regards to checks and bal-
ances.63 As pointed out earlier, however, James Madison’s works 
show that the overarching goals of the Constitution were to ensure 
that each branch possessed the necessary tools to prevent any en-
croachment or any one branch from being capable of overpowering 
																																																																																																																												
 59  See Mikva, supra note 54, at 2.  
 60  Id. 
 61  Id. (quoting THE FEDERALIST NO. 51, at 349 (James Madison) (J. Cooke 
ed., 1961)). 
 62  See Kate Stith, supra note 45, at 1348 (“While section 8 of article I enu-
merates the powers of the legislative branch, the appropriations clause in section 
9 is not a grant of power. Rather, the appropriations clause affirmatively obligates 
Congress to exercise a power already in its possession.”). 
 63  See Mikva, supra note 54, at 1–3. Mikva argues that, because the appro-
priations power is far and away the most powerful and effectual tool in the arsenal 
of any of the three governmental branches, it must mean that the Framers of the 
Constitution actually intended for the legislative branch to truly be the most pow-
erful governing branch of the three. See id. This is obviously at odds with the 
doctrine of separation of powers, but is a helpful argument in demonstrating just 
how far the legislature is able to stretch the appropriations power to push their 
own agenda.  
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another.64 It may be inferred, then, that perhaps the appropriations 
power has been abused in a way that makes the legislature more 
powerful than the executive branch. 
The discretionary power granted upon Congress to make budg-
etary decisions that shape social and fiscal policy is a necessary evil, 
because, in theory, no branch is better suited to consider the diverse 
interests of the people than the legislature elected by the people.65 In 
order for this power to function properly and not run amuck with the 
separation of powers doctrine, however, it can be inferred that Con-
gress’ responsibility in appropriating funds to executive agencies 
should be based on whether or not said appropriations will benefit 
the people, not simply coincide with particular party lines.   
C. How Has Congress Used the Appropriations Clause to Push 
Policy in the Past? 
Although Congress’ method of barring the FDA from reviewing 
any further applications for mitochondrial replacement therapy can 
be described as a questionable use of the appropriations power at 
best, this is hardly the first time that Congress has used the Appro-
priations Clause to advance partisan objectives.66 In fact, Congress 
effectively ended the Vietnam War simply through the exercise of 
its appropriations power.67 
In 1974 and 1975, once Congress had become convinced that the 
Vietnam War needed to end, Congress refused to appropriate the 
more than $500 million requested by President Gerald Ford to con-
tinue the war effort.68 Therefore, the war came to a rather abrupt end 
because Congress’ denial to continue funding the war essentially 
																																																																																																																												
 64  See id. at 2.  
 65  Id. at 4. Mikva believes that “[n]o institution is more willing–no institution 
is better able–to consider and accommodate the[] [diverse interests of its citizens] 
than the legislative branch. The Framers’ decision to give budgetary power to 
Congress rested largely on this view.” Id. 
 66  Id. at 4–5. 
 67  Id. Mikva discusses that for years leading up to the Vietnam War and 
throughout the war, Congress vehemently resisted the “costly and futile foreign 
venture.” Id. at 4. Once Congress was completely convinced that the War had to 
stop, it simply refused to appropriate any more money to the effort, forcing ces-
sation against the executive branch’s wishes. Id. at 4–5. 
 68  Id.  
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forced the cessation of hostilities. 69  In turn, the appropriations 
power authorized Congress to not only make a determination that 
the government cannot afford spending any more federal funds on a 
particular activity—in this case, the controversial war—but it also 
allowed Congress to make a determination that “the specified activ-
ity is no longer within the realm of authorized government ac-
tions.”70  
Unlike the rejection of mitochondrial replacement therapy, Con-
gress’ use of the appropriations power to end the Vietnam War is a 
paradigm of how the Framers intended the power to be used.71 This 
is vastly different than the situation surrounding mitochondrial re-
placement therapy. The Vietnam War represented an issue that di-
vided the entire country72—an issue that resulted in the death of ap-
proximately 58,000 U.S. soldiers.73 Put another way, Congress’ de-
cision to take action had much less to do with accommodating po-
litical ideologies than it did with resolving issues that had significant 
detrimental impacts on many Americans.  
In contrast, curing mitochondrial diseases that impact up to 
4,000 children every year is hardly an issue dividing the people to 
the extent that a Congressional ban seems prudent. Furthermore, if 
the use of federal funds represented a financial issue, as opposed to 
a social policy issue, Congress could have simply barred the use of 
federal funds directly for research purposes but still allowed the 
																																																																																																																												
 69  Id. 
 70  Stith, supra note 45, at 1360–61. 
 71  Mikva, supra note 54, at 4–5 (“The Framers’ decision to give budgetary 
power to Congress rested largely on this view . . . . Clearly, the Framers believed 
that decisions directly affecting the pocketbooks of our people should be made by 
the governmental institution that is closest to them.”). 
 72  Stephen Zunes & Jesse Laird, The US Anti-Vietnam War Movement (1964-
1973), INT’L CTR. ON NONVIOLENT CONFLICT (Jan. 2010), https://www.nonvio-
lent-conflict.org/the-us-anti-vietnam-war-movement-1964-1973/ (“The U.S. war 
in Vietnam triggered the most tenacious anti-war movement in U.S. history . . . . 
[H]undreds of thousands of young people became radicalized in a largely nonvi-
olent, diverse and sometimes inchoate popular culture of war resistance, employ-
ing tactics ranging from comical street theatre to industrial sabotage.”). 
 73  Vietnam War U.S. Military Fatal, Casualty Statistics, U.S. NAT’L AR-
CHIVES & RECORDS ADMIN. (Dec. 20, 2017), https://www.archives.gov/ re-
search/military/vietnam-war/casualty-statistics.html (“The Vietnam Conflict Ex-
tract Data File of the Defense Casualty Analysis System (DCAS) Extract Files 
contains records of 58,220 U.S. military fatal casualties of the Vietnam War.”).  
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FDA to accept applications from clinical trials funded entirely by 
third party payers. The fact that the appropriations requirement is 
only a condition precedent to executive branch action supports the 
notion that it was never intended to be a grant of affirmative power. 
Instead, it was intended to be a limitation on the exercise of legisla-
tive power.74  
III. AN AGE-OLD DEBATE: THE PARTISAN DIVIDE OVER  
ABORTION AND THE TRANSITION TOWARDS EMBRYOS 
A. Republican Opposition to Abortion 
Ever since the Supreme Court decided in Roe v. Wade to grant 
women a limited right to abortion,75 a “culture war” between Re-
publicans and Democrats has raged regarding “the status of life after 
conception and before birth.”76 Prior to Roe, abortion was criminal-
ized by statute as homicide in some states.77 Roe shifted the meaning 
of the term “abortion” from a medical term used by physicians to a 
“public and moral issue of nationwide concern”78  that routinely 
sparks contextual debates regarding human nature and when life 
truly begins.79 I, like others, hypothesize that the divide amongst 
																																																																																																																												
 74  Stith, supra note 45, at 1349–50, 1350 n.28 (“Placement of the appropria-
tions requirement in section 9 is consistent . . . with the dual intent of the framers 
both to limit the power of the executive branch and to restrain the federal govern-
ment as a whole.”). 
 75  410 U.S. 113 (1973). 
 76  Janet L. Dolgin, Surrounding Embryos: Biology, Ideology, and Politics, 16 
HEALTH MATRIX 27, 31 (2006) [hereinafter Dolgin, Surrounding Embryos]; see 
Robin Toner, The Nation: To the Barricades; The Culture Wars, Part II, N.Y. 
TIMES (Feb. 29, 2004), https://www.nytimes.com/2004/02/29/weekinreview/the-
nation-to-the-barricades-the-culture-wars-part-ii.html. At the 1992 Republican 
National Convention, Patrick Buchanan referred to the “cultural war” for the “soul 
of America” between Presidential candidates Bill Clinton and George H.W. Bush 
centered around the ideological differences the two had on abortion. Toner, supra. 
 77  Kayhan Parsi, Metaphorical Imagination: The Moral and Legal Status of 
Fetuses and Embryos, 2 DEPAUL J. HEALTH CARE L. 703, 716–17 (1999). 
 78  KRISTIN LUKER, ABORTION AND THE POLITICS OF MOTHERHOOD 127 
(Brian Barry & Samuel L. Popkin eds., 1984) (emphasis omitted).  
 79  See id. at 158–91 (examining pro-life and pro-choice views); see also Dol-
gin, Surrounding Embryos, supra note 76, at 31 n.26 (“Luker reports that more 
people became part of the movement opposing abortion in the year following Jan. 
22, 1973 (the day on which Roe was decided) than in any other year before or 
after.” (emphasis added)) (citing LUKER, supra note 78, at 137).  
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party lines with regard to abortion is, or at least should be, identical 
to a divide on the issue of mitochondrial replacement therapy be-
cause both involve the manipulation of embryos, and the disruption 
of the natural fetal development process.80 
Today more than ever, abortion remains a contentious issue that 
diverges significantly depending on what side of the partisan line 
one falls on.81  In a recent survey conducted by Pew Research Cen-
ter, sixty-five percent (65%) of Republicans felt that abortion should 
be illegal in all or at least most cases, while seventy-five percent 
(75%) of Democrats felt that abortion should be legal in most 
cases.82 While pro-life advocates have often framed the divide over 
abortion to stand for much larger social debates regarding “moral 
values” and family structure,83 the thrust of most Republicans’ ar-
gument revolves around the personhood status of the fetus.84 Pro-
life advocates have long believed that fetuses and embryos deserve 
better treatment than if they were biological property or tissue of the 
mother because, although they are not “persons” in a strict legal 
sense, they are in fact along a developmental path towards becoming 
persons.85 Put simply, due to their “potential” for personhood, fe-
tuses have always deserved a certain moral and intrinsic status as 
being “part of the continuum of biological human life.”86 The strong 
desire by pro-life advocates to restrict abortion, due to the person-
hood of a fetus, is summarized effectively in a metaphor by Dr. Ste-
ven Maynard-Moody, Director of the Institute for Policy & Social 
Research at the University of Kansas as follows:  
																																																																																																																												
 80  Corey Washington, Mitochondrial Replacement Therapies: Between Abor-
tion and Genetic Engineering, SPARTAN IDEAS (June 3, 2014), http://spartan-
ideas.msu.edu/2014/06/03/mitochondrial-replacement-therapies-between-abor-
tion-and-genetic-engineering/. 
81  Hannah Fingerhut, On Abortion, Persistent Divides Between – and Within 
– the Two Parties, PEW RES. CTR. (July 7, 2017), http://www.pewresearch.org/ 
fact-tank/2017/07/07/on-abortion-persistent-divides-between-and-within-the-
two-parties-2/ (noting that “the partisan divide on abortion remains far more po-
larized than it was two decades ago”). 
 82  See id.  
 83  See Janet L. Dolgin, Embryonic Discourse: Abortion, Stem Cells, and 
Cloning, 31 FLA. ST. U. L. REV. 101, 121–28 (2003) (discussing the broader social 
implications that stem from the abortion debate). 
 84  See Dolgin, Surrounding Embryos, supra note 76, at 31–32. 
 85  See Parsi, supra note 77, at 704. 
 86  Id. at 705. 
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[T]he fetus is not a spleen. Though wholly dependent 
on the pregnant woman and unable to live outside her 
womb, a not-yet-viable fetus is genetically distinct 
from the pregnant woman; it is not an organ or tissue, 
but a body, suggesting to some that it can be defined 
as a person . . . . The view that the fetus is tissue or 
tissue property is founded on complex scientific evi-
dence about human development and legal argu-
ments about torts and rights, whereas the image of 
the fetus as a baby is based on a simple, emotional 
reaction to the form: it looks like a baby.87 
While the historical divide among partisan lines over abortion is 
not the focal point of the potential divide over mitochondrial re-
placement therapy, it is important to understand this divide because 
it represents the same partisan issue that has evolved as scientific 
research has improved: the legal and moral status of embryos.  
B. Republican Opposition to Embryonic and Stem-Cell Research 
With scientific improvements in the medical industry allowing 
us to see further and further down the line of fetal development,88 
the politicization of the debate regarding the personhood of a fetus 
began to evolve a similar politicization of the embryo. 
																																																																																																																												
 87  STEVEN MAYNARD-MOODY, THE DILEMMA OF THE FETUS 86 (1995). 
 88  See Dolgin, Surrounding Embryos, supra note 76, at 34–35 (“Embryos 
came into social consciousness as the result of medical and technological devel-
opments. The first among these developments was increasingly accurate and in-
expensive pregnancy tests that could be used soon after conception, followed by 
the development of ultrasonography which permitted pregnant women, their part-
ners, and their health care providers to visualize the progress of a pregnancy be-
fore the start of the fetal stage. The appearance of an industry in infertility care in 
the late 1970s and early 1980s  played a major role in society’s reconceptulization 
of the notion of embryo.”). 
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When a male reproductive sperm cell fertilizes a female repro-
ductive oocyte, or “egg,” a new cell is formed known as a “zy-
gote.”89 When the zygote cell begins to divide, it becomes an “em-
bryo.”90 The mass of cells that has formed after fertilization contin-
ues to be considered an “embryo” until approximately the eighth 
week of development, at which point the embryo becomes a fetus.91  
The fact that embryos are a cluster of cells—unlike fetuses, 
which more closely resemble babies—has made it difficult for the 
pro-life movement to muster the same strong argument for embry-
onic life as it could for fetal life.92 Despite this, many Republicans93 
and other pro-life advocates such as the Catholic Church have 
staunchly opposed any scientific research efforts that ultimately re-
sult in the manipulation or destruction of embryos.94  
The partisan divide over the philosophical definition of embryos 
is best highlighted by a juxtaposition of Democrat President Clin-
ton’s proposed guidelines on federal funding for stem cell research 
in 2000 with that of Republican President Bush’s opposition in 
2005. Shortly after “U.S. scientists successfully isolated and cul-
tured stem cells obtained from human embryos and fetuses” in 1998, 
“President Clinton approved the National Institutes of Health’s 
(NIH) proposed guidelines to allow federal funding for research on 
stem cells.”95 This federal funding allowed scientists to study the 
effects of introducing healthy stem cells into the body to potentially 
treat many diseases that are caused from the death of dysfunctional 
																																																																																																																												
 89  Egg to Embryo to Fetus: The Reproduction and Development Process, VIS-
IBLE BODY, https://www.visiblebody.com/learn/reproductive/reproductive-pro-
cess (last visited Sept. 20, 2018) [hereinafter Egg to Embryo to Fetus]. 
 90  Id.; see also Simon Fishel, Assisted Conception in the Human – The Em-
bryological View, in CONCEIVING THE EMBRYO: ETHICS, LAW, AND PRACTICE IN 
HUMAN EMBRYOLOGY 15 (Donald Evans & Neil Pickering eds., 1996) (noting 
that an embryo forms approximately twenty-four hours after fertilization). 
 91  Egg to Embryo to Fetus, supra note 89. 
 92  See Dolgin, Surrounding Embryos, supra note 76, at 35. 
 93  See infra text accompanying notes 98–106. 
 94  See Erin P. George, The Stem Cell Debate: The Legal, Political and Ethical 
Issues Surrounding Federal Funding of Scientific Research on Human Embryos, 
12 ALB. L.J. SCI. & TECH. 747, 751 (2002) (“The Catholic Church is opposed to 
IVF because of the method used to collect semen, masturbation, and the fact that 
sexual intercourse is not the procreative function used.”). 
 95  Id. at 748.  
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cells.96 In enthusiastic support of the emergence of stem cell capa-
bilities, President Clinton commented that stem cell research offers 
“potentially staggering benefits,”97 and scientists worldwide have 
commented on the potential benefits as well.98 However, opposition 
to stem cell research often derives not from the potential benefits it 
provides, but from the process required to get there.99 This process 
requires human stem cells to be extracted from human embryos an-
ywhere from seven to fourteen days after fertilization occurs, 
thereby resulting in the death of the embryo.100 
President Bush, on the other hand, strongly opposed all research 
using human embryos, and sought to promptly end all federal fund-
ing of stem cell research.101 In 2005, after announcing that he in-
tended to veto a pending bill that would allow federal funding for 
embryonic stem-cell research,102 President Bush pledged to protect 
those who he deemed “our society’s most vulnerable members.”103 
Other prominent Republican figures have referred to proposed NIH 
guidelines on stem cell research as “a sham” that “attempt to give a 
glow of respectability to truly barbaric and grotesque experiments 
on human beings.”104 As recently as July 2016, the Republican plat-
form has explicitly opposed and condemned embryonic stem cell 
research, announcing at the Republican Convention in July 2016:  
We oppose embryonic stem cell research. We oppose 
federal funding of embryonic stem cell research. We 
																																																																																																																												
 96  See id. at 756. 
 97  Gretchen Vogel, NIH Allows Pluripotent Stem Cell Research, SCI. (Aug. 
23, 2000, 6:00 PM), http://www.sciencemag.org/news/2000/08/nih-allows-pluri 
potent-stem-cell-research [hereinafter Vogel, NIH]. 
 98  See George, supra note 94, at 758. 
 99  See id. at 756.	
 100  See id.  
 101  See id. at 775. 
 102  See US Stem Cell Bill Stalls in Senate, BIONEWS (July 24, 2005), https:// 
www.bionews.org.uk/page_89755; see also Stem Cell Research Enhancement 
Act of 2005, H.R. 810, 109th Cong. (2005). 
 103  Press Release, President George W. Bush, President Discusses Embryo 
Adoption and Ethical Stem Cell Research (May 24, 2005), https://georgewbush-
whitehouse.archives.gov/news/releases/2005/05/20050524-12.html. 
 104  Susan Lee, Harvard Law & Health Care Soc’y, Human Stem Cell Re-
search: NIH Releases Draft Guidelines for Comment, 28 J.L. MED. & ETHICS 81, 
82 (2000) (quoting Representative Christopher Smith, a Republican from New 
Jersey) (emphasis added). 
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support adult stem cell research and urge the restora-
tion of the national placental stem cell bank created 
by President George H.W. Bush but abolished by his 
Democrat successor, President Bill Clinton. We op-
pose federal funding for harvesting embryos . . . .105  
This statement sparked a response from Dr. George Q. Daley, a re-
searcher at the Harvard Stem Cell Institute, who told Bloomberg 
BNA that human embryonic stem cells are “essential” for medical 
research, and that “[i]t would be a major setback should the Repub-
lican Party succeed in turning back the clock to a more restrictive 
stem cell policy.”106  
Even during the first debate of the 2016 Presidential campaign, 
Republican candidates disagreed on every single topic discussed ex-
cept for one: research using fetal tissue cells.107 Such a united front 
against any and all research involving the use of donated embryos 
represents a major hurdle for the scientific community towards im-
proving health and saving lives, especially when bipartisan support 
is needed to secure federal funding or approval. The latest experi-
mental breakthrough to fall victim to Republican opposition: mito-
chondrial replacement therapy. 
C. Why Opponents of Abortion and Embryo Research Are Likely 
Opposed to Mitochondrial Replacement Therapy  
Although virtually no literature currently discusses the division 
over mitochondrial replacement therapy from a political ideology 
standpoint, the similarities in mitochondrial replacement therapy re-
search and stem cell research are clear. Therefore, the same partisan 
group who has historically opposed abortion and various forms of 
																																																																																																																												
 105  Republican Platform Blasts FDA, Seeks Embryonic Stem Cell Ban, RES. 
AMERICA (July 20, 2016), http://www.researchamerica.org/news-events/news/ 
republican-platform-blasts-fda-seeks-embryonic-stem-cell-ban. 
 106  Id. 
 107  Dov Fox, The GOP Case Against Stem Cell Research, HUFFINGTON POST 
(Aug. 7, 2015, 8:35 PM), https://www.huffingtonpost.com/dov-fox/gop-confu-
sion-over-stem-c_b_7958424.html (“The [Republican candidates] disagreed on 
every topic they faced—immigration, health care, foreign policy, gay rights, the 
economy . . . . All 17 [candidates] in [the] debates . . . staunchly opposed research 
that uses tissue cells from aborted or miscarried fetuses.” (emphasis added)). 
322 UNIVERSITY OF MIAMI LAW REVIEW [Vol. 73:300 
embryonic research—the Republican Party—likely opposes mito-
chondrial replacement therapy experimentation as well. Because the 
early experimental stages of mitochondrial replacement therapy in 
human clinical trials would result in the destruction or discard of 
donated embryos, Republicans and pro-life groups are likely to 
equate the treatment of embryos in mitochondrial replacement ther-
apy to the way embryos are destroyed during stem cell research.108  
D. Progress Towards and Success of Mitochondrial Replacement 
Therapy 
Recent evidence from the United States indicates that mitochon-
drial replacement therapy techniques are in fact safe and effective in 
primates.109 However, further research is still necessary to deter-
mine both the safety and effectiveness in humans, as well as the 
long-term effects of mitochondrial replacement therapy.110 In con-
trast, mitochondrial replacement therapy experimentation received 
extensive support in the United Kingdom and, in 2015, the United 
Kingdom Parliament voted to allow mitochondrial donation for the 
purposes of mitochondrial replacement therapy on a case-by-case 
basis.111 Further, in September 2016, the world’s first “three-parent 
baby” was born after successful use of the mitochondrial replace-
ment technique by a United States-based team in Mexico.112 
Although concerns regarding safety and effectiveness inevitably 
will remain, the successful application of the mitochondrial replace-
ment therapy technique performed by Dr. John Zhang and his team 
from New Hope Fertility Center in New York is likely to fast-for-
ward progress from other nations more inclined to accept this re-
search. 113  This successful application involved a patient of Dr. 
																																																																																																																												
 108  See George, supra note 94, at 756. 
 109  See Orcutt, supra note 18. 
 110  UMDF Position & Clinical Status of Mitochondrial Replacement Therapy 
to Prevent Transmission of mtDNA Disease, UNITED MITOCHONDRIAL DISEASE 
FOUND. (Nov. 2017), http://www.umdf.org/mitochondrial-replacement-therapy/. 
 111  Id.  
 112  Jessica Hamzelou, Exclusive: World’s First Baby Born with New “3 Par-
ent” Technique, NEW SCIENTIST (Sept. 27, 2016), https://www.newscientist. 
com/article/2107219-exclusive-worlds-first-baby-born-with-new-3-parent-tech-
nique/. 
 113  See id. (“The controversial technique . . . has only been legally approved 
in the UK. But the birth of the child, whose Jordanian parents were treated by a 
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Zhang’s who carries a gene for Leigh Syndrome, which is a fatal 
mitochondrial disorder that negates healthy development of the 
nervous system.114 After Leigh Syndrome was passed down from 
the mother’s mitochondrial DNA and killed their first two children, 
the couple sought out Dr. Zhang and his team to perform a variation 
of the mitochondrial replacement therapy known as “spindle nuclear 
transfer.”115 Dr. Zhang was able to create five embryos for the cou-
ple, one of which developed normally, and was implanted in the 
mother.116 Nine months later, the child was born healthy, with less 
than one percent of his mitochondria carrying mutated mitochon-
drial DNA, far below the eighteen percent that is generally required 
before problems begin to arise.117  
Furthermore, Dr. Zhang’s approach was met with glowing re-
marks by colleagues in the field.118 Most importantly, the team exe-
cuted the mitochondrial replacement therapy without destroying a 
single embryo, and used only a male embryo so as to avoid any 
chance a resulting female child could later pass on any inherited mi-
tochondrial DNA.119 Dr. Sian Harding, Professor of Cardiac Phar-
macology at the National Heart and Lung Institute,120 stated that Dr. 
Zhang’s work was “as good or better than what we’ll do in the 
																																																																																																																												
US-based team in Mexico, should fast-forward progress around the world, says 
embryologists.”). 
 114  Id.; see also Leigh Syndrome, U.S. NAT’L LIBRARY MEDICINE: GENETICS 
HOME REFERENCE (June 2016), https://ghr.nlm.nih.gov/condition/leigh-syn 
drome. 
 115  See Hamzelou, supra note 111. Hamzelou notes that because of the cou-
ple’s Muslim heritage, they were opposed to the destruction of what would be the 
resulting embryos. Id. Therefore, Zhang performed spindle nuclear transfer, 
whereby “[h]e removed the nucleus from one of the mother’s eggs and inserted it 
into a donor egg that had had its own nucleus removed. The resulting egg – with 
nuclear DNA from the mother and mitochondrial DNA from a donor – was then 
fertilised with the father’s sperm.” Id.  
 116  Id. 
 117  Id.  
 118  See id. (“The team seems to have taken an ethical approach with their tech-
nique, says Sian Harding.”). Sian Harding is a Professor of Cardiac Pharmacology 
at the National Heart and Lung Institute. Professor Sian Harding, IMPERIAL LON-
DON C., https://www.imperial.ac.uk/people/sian.harding (last visited Sept. 22, 
2018). 
 119  Hamzelou, supra note 111. 
 120  Professor Sian Harding, supra note 117. 
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UK.”121 It is a shame, however, that Dr. Zhang and his team had to 
perform the procedure in Mexico, as opposed to New York, in order 
to save this baby’s life.122 
IV. CONGRESS ABUSED ITS APPROPRIATIONS POWER IN ORDER TO 
PRECLUDE FURTHER RESEARCH ON  
MITOCHONDRIAL REPLACEMENT THERAPY 
While it is understandable that Republican and pro-life opposi-
tion towards embryonic research would result in hesitation to 
quickly move forward from research in primates to research in hu-
mans, it was improper for Congress to bar clinical trials in the man-
ner that it did. The preclusion of the FDA to review all public and 
private applications for mitochondrial replacement therapy research 
in an omnibus fiscal bill is a blatant misuse of the appropriations 
power afforded to Congress. Not only does it prevent society from 
receiving the large benefit the research would have, it also likely 
violates the separation of powers doctrine by infringing on authority 
that is rightfully afforded exclusively to the FDA.  
A. The Context Behind How the Ban Was Introduced Is Contro-
versial and Concerning 
As argued previously, the Framers’ intent in granting the appro-
priations power to the legislative branch was to give Congress no 
more authority than necessary to manage123 the “purse” that is the 
federal treasury.124 Although wielding wide discretion to appropri-
ate, Congress’ power was intended to be limited to the extent neces-
sary to prevent abuses in spending by the executive branch and its 
agencies.125 This was meant to serve as a guard against encroach-
ment by the executive branch, not an affirmative weapon to contro-
vert the executive branch.126  
																																																																																																																												
 121  Hamzelou, supra note 111. 
 122  See id. (“Neither method has been approved in the US, so Zhang went to 
Mexico instead, where he says ‘there are no rules[.’] He is adamant that he made 
the right choice. ‘To save lives is the ethical thing to do,’ he says.”). 
 123  See Mikva, supra note 54, at 2. 
 124  See supra Sections II.A., II.B. 
 125  See id. 
 126  See id. 
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The circumstances surrounding the ban encompassing mito-
chondrial replacement therapy are nothing short of suspicious. Con-
gressional Republicans proposed the $1.1 trillion omnibus spending 
bill in a fashion that forced President Obama to sign the bill with 
little time to review because he faced the prospect of a complete 
government shut down.127 The bill, which was over 2,000 pages in 
length,128 contained a vast range of other appropriations that needed 
to be voted on in an “all-or-nothing”129 fashion as part of the annual 
balancing of the federal budget process. Tucked away discreetly in 
a ten-line provision amidst this massive federal spending bill is the 
language that affirmatively preempts the FDA from evaluating mi-
tochondrial replacement therapy research.130 The congressional rec-
ord is completely silent regarding the identities of the sponsors of 
the ban, as well as the precise motives for sneaking it into the bill in 
such a manner.131 There was a “complete absence of discussion be-
fore its passage or at any time thereafter,” despite being included “in 
a must-pass omnibus appropriation bill.” 132 Dr. Eli Adashi has said 
that scientists and other advocates of the research have “no idea how 
the ban’s language even came to be a part of the bill” and that 
“[t]here’s no paper trail, there’s no smoking gun—there is just the 
																																																																																																																												
 127  Tanya Lewis, Congress Just Put a Massive Roadblock in the Way of Ge-
netically Editing Human Embryos, BUS. INSIDER (Dec. 16, 2015, 2:45 PM), 
http://www.businessinsider.com/congress-bans-funding-for-embryo-gene-edit-
ing-2015-12. 
 128  The bill contains 2,009 pages worth of appropriations and conditions. See 
generally H.R. RULES COMM., 114TH CONG., TEXT OF HOUSE AMENDMENT #1 TO 
THE SENATE AMENDMENT TO H.R. 2029, MILITARY CONSTRUCTION AND VETER-
ANS AFFAIRS AND RELATED AGENCIES APPROPRIATIONS ACT, 2016 (Comm. 
Print. 2015). 
 129  See id.; see also Lewis, supra note 126 (“[T]he spending bill also expands 
the National Institutes of Health’s annual budget by $2 billion to a total of $32 
billion, including $350 million for Alzheimer’s research. In addition, the Food 
and Drug Administration will get an additional $133 million for a total of $2.7 
billion, which includes additional funding for President Obama’s Precision Med-
icine Initiative.”).  
 130  See Consolidated Appropriations Act, 2016, Pub. L. 114-113, § 749, 129 
Stat. 2242, 2283 (2015). 
 131  Adashi & Cohen, supra note 9, at 575. 
 132  Id.  
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result.”133 Even the Appropriations Committee spokesperson, Jen-
nifer Hing, refused to comment on where the language came from 
when pressed on the issue by BuzzFeed in 2016.134 
This series of events does not represent a legislative “check” on 
the executive branch’s “wielding of its sword,” as Baron de Mon-
tesquieu and James Madison intended in framing the separation of 
powers doctrine and the Constitution.135 The FDA has served as a 
consumer protection agency since the congressional passage of the 
1906 Pure Food and Drugs Act,136 and possesses plenary authority 
to ensure that food, cosmetics, drugs and medical devices are medi-
cally and nutritionally sound.137 By definition, the appropriations 
power does not explicitly grant the legislative branch authority to 
dictate how executive agencies enforce the law, yet that is seemingly 
what the condition attached to Section 749 of the Consolidated Ap-
propriations Act of 2016 aimed to do by outlawing any reviews of 
applications for particular medical research.138 Congress is author-
ized by the Constitution to deny appropriations, and quite frankly, 
should be encouraged to if federal funds are sought in an encroach-
ing manner or for a particular activity that does not serve the best 
interests of the people. Reviewing clinical applications for privately 
funded medical research that can save thousands of lives every year, 
however, does not match that description.  
B. The Congressional Ban Was Just as Careless  
as It Was Purposeful 
There is no denying that the language of Section 749 of the Con-
solidated Appropriations Act of 2016, which prohibits the FDA 
from reviewing applications “in which a human embryo is intention-
																																																																																																																												
 133  See Subbaraman, supra note 6.  
 134  Id.  
 135  See supra notes 54–56. 
 136  See When and Why Was FDA Formed?, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/AboutFDA/Transparency/Basics/ucm214403.htm (last up-
dated Aug. 22, 2018). 
 137  Ben Panko, Where Did the FDA Come From, and What Does It 
Do?, SMITHSONIAN.COM (Feb. 8, 2017), https://www.smithsonianmag.com/ sci-
ence-nature/origins-FDA-what-does-it-do-180962054/. 
 138  See Consolidated Appropriations Act, 2016, Pub. L. 114-113, § 749, 129 
Stat. 2242, 2283 (2015). 
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ally created or modified to include a heritable genetic modifica-
tion”139 grounds any further research on mitochondrial replacement 
therapy in the United States for the time being. However, what if 
mitochondrial replacement therapy was not the intended target of 
the Republican Congress’ misuse of the Appropriations Clause? Is 
careless crafting of a budget bill that handcuffs the FDA’s adminis-
trative authority to regulate an area of scientific research any less 
damaging than a purposeful and sneaky effort to tuck such a divided 
and controversial provision into a colossal omnibus bill without any 
explanation for its inclusion?  
Some experts in the field, such as Dr. Eli Adashi, believe that 
there is a strong likelihood that Congress’ primary target was not, in 
fact, mitochondrial replacement therapy, but a more controversial 
genetic technology known as “CRISPR.”140 CRISPR technology is 
much more in line with the traditional fears held by Republicans and 
pro-life advocates that scientists will try and “play God”141 by engi-
neering “designer babies” through the direct manipulation of the hu-
man genomes.142 CRISPR is significantly more controversial than 
mitochondrial replacement therapy because rather than swapping 
out already existing DNA with DNA from another person in order 
to prevent the passage of a disease, “CRISPR targets specific genes 
in the code to delete or ‘edit,’” thus leading to the fear of future “de-
signer babies.”143  
This contentious technology possesses the sort of social and eth-
ical concerns that the Framers likely would have had in mind when 
giving the legislative branch authority to deny appropriations to ex-
ecutive agencies. Yet, the perhaps unintended consequence of the 
																																																																																																																												
 139  Id.  
 140  See Subbaraman, supra note 6.  
 141  Loike & Reame, supra note 29. 
 142  See Subbaraman, supra note 6; see also Questions and Answers About 
CRISPR, BROAD INST., https://www.broadinstitute.org/what-broad/areas-focus/ 
project-spotlight/questions-and-answers-about-crispr (last visited Sept. 19, 2018) 
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 143  See Subbaraman, supra note 6. 
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way in which Congress drafted the budget bill in 2016 precluded not 
only CRISPR, but other areas of genetic research that do not pose 
vast ethical dilemmas and partisan divisions. It was very feasible at 
the time the bill was passed for the drafters of the bill to deny appro-
priations for FDA review of applications for CRISPR research, 
without simultaneously precluding mitochondrial replacement ther-
apy research in the process. 
Even if Congress’ outright ban on genetic modification research 
on human embryos was aimed at CRISPR with good intentions, it 
was clearly ineffective and, quite frankly, unnecessary. Many scien-
tists today are in agreement that testing CRISPR germline editing in 
humans is nothing short of ethically impermissible and “irresponsi-
ble at this point.”144 Furthermore, a global committee consisting of 
gene-editing experts and ethicists, which convened at the Interna-
tional Summit on Human Gene Editing in 2015 concluded that cre-
ating gene-modifications in humans cannot go forward until the 
safety is established and there is a “broad social consensus on 
whether such a step is desirable.”145 David Baltimore, a Nobel Prize-
winning biologist at the California Institute of Technology, stated 
that “[t]he human genome is shared among all nations . . . . [Safety 
and social/ethical consensus] criteria have not been met for any pro-
posed clinical use.”146  
If CRISPR was the target of the language in the bill, it was su-
perfluous for Congress to seek to bar any research efforts of this type 
when the scientific community is seemingly in agreement that it is 
unsafe and unethical to further research efforts in the first place. 
Moreover, the way in which Congress chose to attack CRISPR was 
also imprudent and reckless because it barred further research on 
mitochondrial replacement therapy. Whether Congress purposefully 
targeted mitochondrial replacement therapy based on partisan view-
points towards personhood and embryonic research or whether mi-
tochondrial replacement therapy was an unintended casualty of an 
intended ban on CRISPR does not change the fact that Congress 
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abused its appropriations power in the process. Regardless of Con-
gress’ true intent, Congress did not trigger its appropriations power 
to prevent the executive branch from spending money at will and 
pushing its own policies and agenda, as the Framers originally in-
tended the power to be used. Instead, Congress affirmatively barred 
a federal agency from reviewing applications for privately funded 
research that is safe, ethically permissible, and has the potential to 
help save thousands of lives.  
V. FUTURE RECOURSE AND THE RECOMMENDED NEXT STEPS FOR 
THE FDA 
As pointed out in Part I, to date, there has been no judicial en-
forcement of the Constitution’s appropriations requirement against 
Congress itself,147 and it is therefore unclear if and how Congress 
can even be found in violation of Article I, Section 9.148 In fact, any 
judicial challenge to the spending authority of Congress is likely 
doomed based on the Supreme Court’s indication that “Congress has 
absolute authority to construe and to effectuate the appropriations 
requirement.”149 While it is relatively clear that the executive branch 
violates the Appropriations Clause if it spends funds not appropri-
ated by Congress or based on Congress’ limitations, it is not entirely 
clear how Congress can be said to “violate” the Appropriations 
Clause. Such a violation would likely arise by legislating open-
ended spending authority in areas in which the executive branch 
bears substantial discretionary power.150  
A judicial challenge to the congressional ban on gene editing 
research involving human embryos is almost guaranteed to fail, 
based on the historical context in which the appropriations power 
has been construed.151 In United States v. Richardson, the Supreme 
Court held that Congress has “plenary” authority to implement the 
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very similar “Statement and Account” clause involving appropria-
tions for the CIA.152 In Harrington v. Bush, a congressman’s chal-
lenge alleging that the CIA was using its secret appropriations for 
unauthorized activities was dismissed for lack of standing,153 but not 
before the Court suggested that Congress has “plenary” authority to 
interpret Article I, Section 9, “including the appropriations clause, 
and that the courts therefore have no power to consider the constitu-
tional adequacy of spending legislation.”154 Clearly, the Court has 
decided that the judicial branch is not positioned or constitutionally 
capable of definitively determining what role independent executive 
agencies should have in developing the federal budget. 
This predicament does not foreclose the motive or opportunity 
the FDA, and others in the field, should have to lobby Congress for 
a much more specific bill that would allow mitochondrial replace-
ment therapy research to go forward with caution. Although the all-
encompassing language used in Section 749 of the Consolidated Ap-
propriations Act of 2016 includes technologies like mitochondrial 
replacement therapy and CRISPR based on strict interpretation of 
the terminology used, the bill does not specifically ban “mitochon-
drial replacement therapy” or “CRISPR” by name.155 Due to the fact 
that mitochondrial replacement therapy is only used to prevent the 
passage of heritable deadly mitochondrial diseases,156 as well as the 
relative progress that has been demonstrated by research in other 
countries thus far,157 it is not farfetched to suggest that Congress 
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 155  See Consolidated Appropriations Act, 2016, Pub. L. 114-113, § 749, 129 
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may be receptive to legislation that creates a narrow, specific excep-
tion to Section 749 of the Consolidated Appropriations Act for mi-
tochondrial replacement therapy research. 
As far as lobbying Congress for reconsideration of the ban 
against mitochondrial replacement therapy goes, the most effective 
recommendation the FDA could offer as a starting point likely 
comes in the same form as the original recommendation the expert 
panel from the National Academies of Sciences made to the FDA in 
2016 before the congressional ban was unveiled.158 This proposal 
would effectively address the ethical, social, and political issues sur-
rounding mitochondrial replacement therapy in a way that may con-
vince even a Republican Congress to allow preliminary clinical tri-
als to proceed. 
First, the panel recommended that federal regulation be imple-
mented, along with principled professional society guidelines to in-
terpret said regulations, to limit any use of mitochondrial replace-
ment therapy strictly to the prevention of life-threatening mitochon-
drial diseases.159 This safeguard would assure that research is con-
ducted for the prevention of disease, and would help convince those 
that misconstrue this technology as analogous with other gene-edit-
ing techniques like CRISPR, that this research would not ultimately 
lead to the ethical melting pot that is “designer babies.” 
Second, despite the inevitable ethical, social, and political de-
bates associated with research that involves the manipulation and 
destruction of donated embryos, responsible use of said embryos in 
clinical research of mitochondrial replacement therapy through eth-
ical frameworks that have already been developed would give at-
risk women an opportunity to have genetically related children with 
a significantly reduced risk of that child having mitochondrial dis-
eases.160 Despite the unavoidable divide among many people re-
garding the use of donated human embryos for clinical research, it 
speaks volumes that a diverse panel of experts in both science and 
ethics have concluded that at this point it is “ethically permissible to 
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conduct clinical investigations of [mitochondrial replacement ther-
apy] subject to certain conditions and principles.”161  
Lastly, the “slow, cautious approach,” recommended by the ex-
pert committee from the Institute of Medicine and outlined below, 
is the most reasonable way to address the “ethical, social, and polit-
ical concerns” many critics of mitochondrial replacement therapy 
share.162 Specifically, the aforementioned expert committee main-
tains that the FDA should begin to consider mitochondrial replace-
ment therapy clinical applications only when all health and safety 
risks are minimized, and the “[l]ikelihood of efficacy is established 
by preclinical research using in vitro modeling, animal testing, and 
testing on human embryos as necessary.” 163  Furthermore, these 
clinical studies should be limited exclusively to women who are 
“undisputed[ly]” at risk for transmitting “severe” mitochondrial dis-
eases “characterized by early mortality or substantial impairment of 
basic function.”164 Additionally, the expert committee proposes lim-
iting initial testing to the gestational transfer of male embryos “to 
prevent potential adverse and uncertain consequences of mitochon-
drial replacement therapy from being passed on to future genera-
tions” via female offspring.165 Lastly, in order to uphold ethical prin-
ciples and medical standards, all initial clinical applications should 
be reserved exclusively to researchers with “demonstrated expertise 
in and skill with relevant techniques.”166  
CONCLUSION 
Regardless of what side of the line one falls on when defining 
the personhood of an embryo, the ethics of embryonic donation and 
research, or the future of genetic manipulation and engineering, 
there is no denying that Congress’ premature decision to take a firm 
stance on these matters through Section 749 of the Consolidated Ap-
propriations Act of 2016 precluded thousands of helpless families 
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 165  Id.; see Vogel, For Boys Only?, supra note 20 (“[T]he panel recommended 
that only altered male embryos should be used to attempt a pregnancy, to limit the 
possible risks to future generations . . . [because] [m]ales can’t pass along mito-
chondrial DNA that is altered in the procedure.”). 
 166  INST. OF MED., supra note 12, at 3–4. 
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from pursuing what could turn out to be life-saving technology for 
their future children. Rather than stand firmly in the sand on what 
has historically been the Republican ideology towards life and per-
sonhood in regards to fetuses and embryos by directly legislating on 
the matter, Congress controversially and strategically tucked this 
ban away ever so subtly in a colossal financial bill without leaving 
any trace as to who actually introduced the ban, or why.  
This blatant exercise of partisanship and policy implementation 
is directly adverse to the purpose of the Appropriations Clause as 
envisioned by the Framers—a passive check necessary to prevent 
encroachment on Congress’ management of the purse by the execu-
tive branch. “Management” of the purse, however, should not be 
synonymous with complete dictation over the executive branch’s 
ability to use the purse to carry out its own policies and responsibil-
ities. Such tolerance of complete and utter legislative control is a 
flagrant violation of the separation of powers doctrine that can and 
will stall progress in a variety of ways. Mitochondrial replacement 
therapy can prevent thousands of women in the United States from 
passing along fatal heritable mitochondrial diseases to their chil-
dren. For now these women are forced to travel to foreign countries 
to seek any form of medical recourse. This is because, instead of 
coming to an agreement over the obvious benefits that mitochon-
drial replacement therapy provides, Republicans and Democrats 
alike harp over the divergent philosophies towards the research re-
quired to get to the finish line.  
